Newsbenzinga
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
· Published
Article summary
AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
An excerpt from the original article.
Comments —
Loading comments…